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ABSTRACT 
 
BACKGROUND: 
The Ketogenic Diet (KD), is a high fat, low carbohydrate dietary regimen, that has been shown 
to treat a diverse array of medical conditions, most notably the seizure associated with epilepsy. 
Recent studies have demonstrated that in addition to reducing seizure frequency, the KD has 
antiepileptogenic effects that continue after reversal to control diet (CD). Such results indicate 
that the KD does not only suppress seizures in adult mice and rats, but it is potentially effective 
in attenuating long-term disease progression. Furthermore, studies on autism spectrum disorder 
(ASD) in a murine mouse model (BTBR mice) found that KD treatment improved autistic 
behaviors by increasing sociability in a three-chamber test and decreasing self-directed repetitive 
behavior. This study will use the BTBR mouse model to determine if improvement in ASD-
associated behaviors persists when animals are returned to a CD. 
  
METHODS: 
BTBR mice at 5 weeks of age were randomly assigned to one of three diet groups: CD, KD, and 
KD reversal. All mice underwent three-chamber behavioral testing (a test of sociability and self-
directed repetitive behaviors in autistic models of mice) followed by two periods lasting three 
weeks. During the first period, both KD group and KD reversal groups were switched to KD for 
three weeks and underwent three-chamber behavioral testing. Subsequently, both groups 
underwent three additional weeks of KD, however in the last 5 days of the second period the 
reversal group was reverted to the CD and underwent their final three-chamber behavioral test. 
Body weights and blood chemistry (glucose and ketone levels) of each mouse was measured 
before treatment (five weeks of age; Test 1) as well as after three weeks of diet administration 
(eight weeks of age; Test 2) and after 6 weeks of diet administration (eleven weeks of age; Test 
3). 
  
RESULTS: 
Although it was expected that enhanced sociability would be observed and continue after 
reversal to the CD, no significant improvements in sociability (characterized by ratio of phase 2, 
preference for sociability phase, compared to phase 1, the non-social phase) were found in any 
treatment group. Blood analysis revealed the hallmark characteristics of  KD treatment, including 
weight loss, decreased glucose, and increased β –hydroxybutyrate levels were found in the KD 
and KD reversal group in Test 2. Additionally, weight glucose, β –hydroxybutyrate levels 
returned to baseline levels after 5-day reversal to CD. 
  
CONCLUSION: 
Despite detected metabolic changes induced by the KD, no notable improvements in sociability 
were detected when the entire sample size was analyzed. These data conflict with previous 
research thus ongoing research will consider methodological differences and include additional 
measures of sociability including frontal contact and self-directed repetitive behaviors.  
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INTRODUCTION 
  
Autism Spectrum Disorder 
 Background 
Autism Spectrum Disorder (ASD) is a chronic neurodevelopmental syndrome that 
emerges in early childhood and affects day to day functioning (Christensen, 2012).  ASD, as 
described in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), is 
characterized two main symptoms; persistent social communication impairment and restricted 
and repetitive patterns of behavior (Melmed &Cubells, 2016). Within the past two decades the 
global prevalence of ASD has increased twentyfold; in the United States alone, the Autism and 
Developmental Disabilities Monitoring (ADDM) Network estimates prevalence of 1 in 68 
children aged 8 years (Simonoff et al, 2007; Jon Baio, 2010).  
 
Impact 
According to the Center for Disease Control (CDC), ASD occurs in all racial, ethnic, and 
socioeconomic groups and is about 4.5 more common in males (Christensen, 2012). The 
economic burden of ASD is tremendous and additive throughout life as disorders on the autistic 
spectrum are lifelong conditions with both direct (medical care) and indirect costs (parental loss 
in productivity). Reportedly, the total direct cost per year for children with ASD is between 
$11.5-$70 billion US dollars (Lavelle et al., 2014). Moreover, the physiological and behavioral 
problems associated with ASD - sleeping disturbances, tantrums, self-harm, etc. -  are correlated 
with poor psychological health of other family members, namely mothers (Goin-Kochel, 2007; 
Hastings, 2003). 
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Emergence of Autism 
The medical diagnosis of autism has been used for over a century beginning in the 1900s 
with the psychiatrist Eugene Bleuler. Although he studied schizophrenia, Bleuler coined the term 
autism to denote the social withdrawal symptoms associated with schizophrenia (Melmed & 
Cubells, 2016). In 1943, the term autism was adapted by psychiatrist, Leo Kanner, who studied 
mentally disabled children. Kanner published a paper that described case studies of highly 
intelligent children that were preoccupied with their own internal world and displayed Bleuler's 
concept of autism. Importantly, Kanner made a distinction between the developed autism in 
schizophrenic patients and children born with “infantile autism” who displayed disruptions in 
emotional expression and lack of empathy (Kanner, 1943). Around this same time, Hans 
Asperger discovered a condition that appeared to be a less severe form of autism which also 
included high functioning intellectual abilities. However, lack of social and emotional reciprocity 
and other social communication impairments among patients led to the separate diagnosis of 
Asperger’s syndrome (Asperger & Firth, 1991).  
  
Diagnostic Criteria   
Autism was not incorporated into the DSM as a separate diagnostic category until the 
third edition in 1987. At this point, a checklist of criteria for diagnosing autism was included and 
focused on three main deficits: (a) social reciprocity, (b) communication, and (c) special 
interests/repetitive behaviors. In 1994, the fourth edition of the DSM was created and included a 
revised definition of autism which now fell into the overarching category of pervasive 
developmental disorders (PDD). PDD included five subcategories: (a) autistic disorder; (b) 
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Asperger disorder; (c) Rett’s syndrome; (d) childhood disintegrative disorder; and (e) PDD-not 
otherwise specified (NOS) (Melmed &Cubells, 2016). 
The most recent change to the fifth edition of the DSM was published in 2013 and 
eliminated all subcategories. As of now, the previous PDD subcategories create a single 
condition known as Autism Spectrum Disorder. The chart in Table 1 outlines the severity levels 
that create the spectrum. Thus, ASD is not a single condition, but a collection of 
neurodevelopmental disorders. There are no current physiological or diagnostic tests to 
determine if individuals fall on the spectrum, only behavioral methods are available for detecting 
ASD. Thus, careful parental monitoring of unusual patterns of early development is the first line 
for screening for ASD (Melmed &Cubells, 2016). 
Table 1: Severity levels for autism spectrum disorder (Melmed &Cubells, 2016). 
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Etiology of ASD 
Many studies have aimed to pinpoint the biological underpinnings of ASD, yet a known 
molecular mechanism of the disorder remains unidentified. Despite this uncertainty, both genetic 
and environmental factors have been shown to play a role in the pathogenesis of ASD. Studies 
on siblings have been instrumental in uncovering the heritability of neurodevelopmental 
disorders. A recent study found concordance rates for ASD among identical twins (that share 
100% of their genetic material) to be significantly higher than concordance rates of both fraternal 
twins and non-twin siblings (both share 50% of their genetic material): 80%, 30%, and 20%, 
respectively (Rosenberg et al. 2009). 
 
Genetic Role   
Although the high concordance rate suggests a strong genetic role, it has been found that 
autism is genetically heterogeneous, as there is only 5% of a shared genetic alteration (Voineagu 
et al. 2011). Furthermore, a comprehensive study in the genomic DNA of patients with ASD 
found that within their sample of 264 families, no genomic variants were identified more than 
twice, suggesting genetic alterations at multiple loci can contribute to the pathogenesis of ASD 
(Sebat et al, 2007). With this study in mind, Morrow et al. mapped several loci and determined 
that a common mechanism that ties together the numerous distinct gene mutations is activity-
dependent gene expression (Morrow et al 2008). Although many different mutations are 
implicated, it is the shared effect on synaptic development that may be responsible for the 
symptoms of ASD. This idea is the basis of the Rare Allele-Common Disease Theory, which 
proposes that rare “private mutation” within families ultimately creating a genetic susceptibility 
for common higher order impairments associated with ASD (Schork et al. 2009). 
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Additional studies have uncovered changes in social behavior in individuals with autism-risk 
alleles that carry genetic risk factors yet are unaffected by ASD. For example, it was found that 
certain identified risk alleles have been associated with higher cognitive abilities based on IQ. 
This suggests a relationship between genetics and disorders on the autism spectrum, such as 
Asperger syndrome (Clarke et al., 2016). Furthermore, a parent-rated scale of social and 
communication impairments indicated that a genetic risk for ASD was associated with altered 
behavior despite clinical diagnoses of ASD (Robinson et al., 2016). Together, these studies 
suggest a genetic component of ASD that makes an individual susceptible to the disorder, yet 
additional environmental influences are responsible for the actual onset of the disorder (Nardone 
& Elliott, 2016). 
 
Environmental Role 
Since 1970, there has been a reported increase in the rate of diagnosed ASD within the 
United States. This trend has been similarly identified in the U.K. and has fueled the idea that 
some environmental factors may play a strong role in the increasing incidence of autism (Blaxill, 
2004). Studies analyzing exposure to certain environments have identified many factors in 
association with increased frequency of ASD diagnoses. Notably, exposure to specific 
teratogens, including thalidomide and valproic acid, have been linked to an increased risk of 
ASD. In the 1960s, thalidomide was prescribed to treat anxiety disorders as well as morning 
sickness for pregnant women (Miller, 1991). However, it was discovered that along with 
congenital disorders inducing malformation of the limbs, approximately 5% of the children 
exposed to thalidomide in their prenatal environment also developed ASD (Matsuzaki et al., 
2012). Similarly, it was found that pregnant women using valproic acid to treat disorders 
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including epilepsy, migraines, and bipolar disorder, had an 8.9% increased likelihood of having 
have a child with ASD (Rasalam et al., 2005). Although the exact mechanism is unknown, it is 
clear that thalidomide and valproic acid in the prenatal environment is associated with increased 
risk of ASD. 
In addition to environmental toxins, maternal diabetes, advanced parental age, low birth 
weight, and multiple births are all prenatal risk factors for ASD (Hallmayer et al. 2011). 
Postnatally, gastrointestinal abnormalities, viral or bacterial infection, zinc deficiencies, and 
abnormal melatonin synthesis have all been associated factors of individuals with disorders on 
the autistic spectrum (Grabrucker, 2012).  
Recent studies regarding prenatal risk factors have led to assessment of maternal health in 
relation to offspring risk for development of ASD.  In a study surveying Danish births from 1980 
to 2005, it was found that expectant mothers hospitalized for viral infections (i.e. flu, 
chickenpox, rubella, etc) during their first trimester of pregnancy had a threefold increase in the 
incidence of  giving birth to a child diagnosed with ASD (Atladóttir et al., 2010). Similarly, a 
report of Swedish births found a 30% increase in ASD when the mothers were hospitalized for 
viral infections during pregnancy (Lee et al., 2014). However, unlike the Danish study, this 
investigation reported a significant effect for an association between ASD diagnosis and viral 
infection in all trimesters of pregnancy. Such studies regarding viral infections and immune 
activation supports possible immune-mediated mechanisms as the biological underpinnings of 
ASD.  
  In addition to maternal viral infection, a recent study suggests that the presence of 
maternal autoimmune disorders may also be a risk factor for ASD. Atladottir et al. examined 
nearly 700,000 Swedish births and discovered that children diagnosed with ASD was associated 
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with maternal autoimmune disorders such as Rheumatoid Arthritis, Celiac Disease, and those 
with a family history of Type 1 Diabetes (Atladóttir et al., 2009). Furthermore, an overall study 
using the Swedish health registry, Keil et al. analyzed maternal health in relation to prenatal 
health and discovered there was a 60% increase in the odds for developing ASD for children 
born of mothers with autoimmune disorders (Keil et al., 2010). Although these studies link 
maternal immune activation and the development of offspring with ASD, they do not determine 
the exact mechanism.  
It is speculated that immune response activation plays a role in the etiology of ASD 
through epigenetics. Epigenetic regulation represents changes in gene expression by factors other 
than DNA sequence (Simmons, 2008; Egger et al., 2004). As stated by Goldberg et al., 
epigenetics is a recently studied phenomenon that represents changes in the final outcome of a 
locus or chromosome without changing the underlying DNA sequence (Goldberg et al., 2007). 
DNA methylation and histone modification are two commonly studied epigenetic markers as 
they impact gene expression without altering the sequence of DNA (Nardone and Elliott, 2014). 
DNA methylation is responsible for alteration in DNA-protein interaction which increases gene 
silencing and may also influence levels of gene transcription, while histone methylation modify 
chromatin structure to influence patterns of gene expression (Jones & Takai, 2001; Goldberg et 
al., 2007). These markers are present during brain development and are associated with periods 
of neural plasticity, thus is speculated that environmental factors such as viral infections during 
natal development, toxins, or maternal autoimmune disease may induce epigenetic changes that 
do not alter genotype yet have a profound effect of phenotype (Spiers et al., 2015; Goldberg et 
al., 2007).  Ultimately, these findings suggest that both the maternal environment and external 
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environmental factors play a role in epigenetic changes that may be responsible for the biological 
underpinnings of ASD (Egger et al., 2004).  
 
 
Neuroanatomical effects of ASD 
Despite an inconclusive mechanism, research has demonstrated genetic, environmental, 
and epigenetic basis of the etiology of ASD. Although the biological underpinnings remain 
unclear, neuroanatomical differences have been identified. In a comprehensive case study of five 
adults with ASD, post mortem ultrastructural brain tissue was studied in three core areas 
implicated in the pathology of ASD: the anterior cingulate cortex, orbitofrontal cortex, and 
lateral prefrontal cortices. When comparing the anterior cingulate cortex (ACC), a decrease in 
diameter of long-range axons was discovered among the individuals with ASD (Casanova, 
2004). 
Compared with control tissue, higher density of medium and short axons within the ACC 
due to increased axonal branching was discovered suggesting an over-connection of prefrontal 
regions in ASD. This finding is consistent with previous studies that propose that increased 
density and branching of short and medium axons is a compensatory mechanism to maintain 
connectivity because of decreased long-range axons that affect signal transmission delays 
(Casanova, 2004). Furthermore, the excessive cortico-cortical connectivity is inadequately 
selective and poorly synchronized leading to impairments in integrating information (Courchesne 
& Pierce, 2005). 
Within the orbitofrontal cortex (OFC), axons of the individuals with ASD had decreased 
myelin thickness which suggests decreased signal conduction speed. Within the lateral prefrontal 
cortices (LPFC) no significant differences were discovered (Casanova, 2004). Together, the 
ultrastructural brain findings provide an outcome of the biological mechanism that underlies 
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ASD. Inadequate long-range axons, excessive expression of short and medium axons, and 
decreased myelin thickness in prefrontal regions may explain help explain the etiology of ASD 
and the resulting impairments in social communication and repetitive patterns of behavior 
(Zikopoulos & Barbas, 2010). 
 
Comorbidity 
Mental retardation and epilepsy are distinct neurological conditions that often co-occur 
with ASD. In a comprehensive study, 30% of patients experienced no mental impairment, 30% 
experienced mild to moderate impairment, while 40% experienced profound mental retardation 
(Fombonne, 2003).  In term of epilepsy, it was found that 40% of children diagnosed with ASD 
have some form of epilepsy (Gabis et al., 2005). Other behavioral conditions associated with 
ASD include hyperactivity, anxiety, depression, and sleeping disturbances (Shaw et al., 2014). 
Reportedly, children with ASD have increased likelihood of experiencing a variety of ailments 
that effectively worsen the core symptoms of ASD. For example, individuals with disorders on 
the autistic spectrum are 1.8 times more likely to have asthma and food allergies, 1.6 times more 
likely to have skin allergies, 2.5 times more likely to have severe headaches, and 3.5 times more 
likely to have colitis (Melmed & Cubells, 2016). 
 
Treatment Methods for ASD 
Background  
There is currently no known cure for ASD. Moreover, because it is often difficult for 
clinicians to address the variable manifestations of ASD, an array of treatment methods has been 
created to address the core symptoms of autism: persistent social communication impairment and 
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restricted and repetitive patterns of behavior. Current treatment methods include most commonly 
behavioral therapy, educational intervention, and drug treatment. A combination of early 
behavioral intervention, including speech and language therapy, and educational programming is 
regarded as the most common and effective treatment for ASD, targeting the core symptoms 
(Autism Speaks). Drug treatments such as the atypical antipsychotic risperidone may improve 
sensory motor behaviors of autism however it had no effect of social communication 
impairments (McDougle et al. 2005). Alternative treatments include specific diets, mind-body 
interventions, energy therapies using electromagnetic fields, and homeopathy (Lofthouse, 2012). 
 
The Ketogenic Diet  
Background  
The ketogenic diet (KD) is an alternative metabolic therapy developed in the 1920s to 
treat refractory epilepsy. The diet was created after Dr. Conklin, an American osteopathic 
physician, found that starving the body of food reduced seizure frequency in his pediatric 
patients (Freeman, Kossoff, & Hartman, 2007). It was further determined by Russell Wilder of 
the Mayo Clinic in 1921 that a diet consisting of high fat-content foods, adequate protein, and 
insufficient levels of carbohydrate for metabolic needs would provide appropriate nutrition, yet 
mimic the biological process of starvation resulting in seizure reduction (Veech, 1004; Barborka, 
1928). The original KD was composed of 4:1 lipid: non-lipid ratio with 80% fat, 15% protein, 
and 5%  carbohydrate (Napoli et al., 2014).  
The diet was used effectively by clinicians until the 1940s when new anticonvulsant 
drugs, such as Dilantin, were put on the market. It is notable that breakthrough seizures can 
occur when carbohydrates are reintroduced into the diet thus strict maintenance of the KD is 
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required for efficacy (Huttenlocher, 1976). With increased drug development, there was a push 
from pharmaceutical companies and physicians as well to move away from seemingly stringent 
treatment methods, such as the KD, and more towards drug treatments. As the KD took the 
backseat to various pharmaceuticals, it was prescribed less frequently thus physicians became 
less experienced with the diet. This lack of experience contributed to the misconception that the 
KD did not work and was difficult to tolerate (Vining et al., 1998).   
  Although the KD continued to be used clinically in a handful of seizure clinics, a larger 
reemergence of the KD began in the 1980s after a famous producer, Jim Abrahams founded the 
Charlie Foundation to Cure Pediatric Epilepsy, named after his son with refractory epilepsy 
(Vining et al., 1998). After trying multiple drug treatments for his son, Abrahams learned about 
the KD and brought his son to John Hopkins Hospital to begin the metabolic therapy. Shortly 
after diet administration, Abrahams was astounded that his son's seizures stopped. Amazed that a 
dietary regimen could have such a profound impact on his son’s health, Abrahams began the 
Charlie Foundation to spread awareness regarding the beneficial effects of the diet.  
In 1994, with funding from the Charlie Foundation, a multicenter study of the efficacy of 
the KD was conducted in order to create a standardized protocol for the KD and assess 
outcomes. Careful analysis of 7 medical centers with a total of 51 pediatric epilepsy patients on 
the KD revealed that the majority of patients that remained on the KD for one year had a up to a 
90% decrease in seizures. Remarkably, each center had at least 1 patient become seizure free. 
This study demonstrated that not only was the diet efficacious, but following the similar 
protocols the rate of success of the KD was similar among different centers. Despite new 
anticonvulsant medications, studies on the efficacy of the KD provided evidence that for children 
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with refractory epilepsy the success rate of the KD exceed the efficacy of pharmaceutical 
treatments (Vining et al., 1998).  
Today, the Johns Hopkins Protocol still exists but has been modified since the early 
1990s. Some of these modifications include: lowered lipid: non-lipid ratio, decreased caloric 
intake from fat (~60-70%), and fat provided as triglycerides esterified with medium-chain fatty 
acids to address deficits in carnitine metabolism (Kossoff et al., 2007; Liu et al., 2013). Studies 
on pediatric children of various ages have determined that a 4:1 ratio is typically more 
efficacious for younger children and a 3:1 ratio is typically more efficacious for older children 
(Zupec-Kania & Spellman, 2008). Below, Tabel 2, adapted from Zupec-Kania & Spellman 
(2008), shows an average day on the KD for a three year old pediatric patient.  
Table 2: A typical day on the ketogenic diet for a 3-year-old child. Note that the majority of fats 
are from heavy cream, vegetable oils, and butter, which represent medium and long chain 
triglycerides. Adapted from Zupec-Kania & Spellman, 2008.  
 
 
Ketogenic Diet Mechanism of Action:  
As previously mentioned, in the early 1920s Dr. Conklin found that starvation was an 
effect treatment for reduction of seizure frequency in his pediatric patients. It is generally 
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accepted that the KD mimics the chronic state of ketosis that is similarly induced by starvation. 
This occurs by changing the body’s form of metabolism, switching from the use of carbohydrate 
and proteins as the primary metabolic fuel to using the high fat stores (Zupec-Kania & Spellman, 
2008). When glucose is not available, mitochondrial β-oxidation of fatty acids in the liver 
produces ketone bodies in the form of acetoacetate and β-hydroxybutyrate (BHB) (Laffel et al., 
1990).  
The biochemical metabolism of ketone bodies include ketogenesis in the liver and allows 
for this fat-derived energy to be used in various organs, most notably the brain. A simple over-
night fast would generate ketone bodies which would meet approximately 2-6% of the body’s 
energy requirements, the rest would be provided by stores of glycogen. After a three day fast, 
about 30–40% of the energy needs would be supplied by ketones (Laffel et al., 1990). In addition 
to increased blood ketone levels, other metabolic effects of the KD include reduced blood 
glucose and increased mitochondrial function (Ruskin et al., 2013).    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The image outlines the metabolic pathway responsible for the production of ketone bodies 
during fasting or treatment with the KD. During fasting and KD there is increased acetoacetate, acetone, 
and β-hydroxybutyrate (relative concentrations are present in the boxes). Due to this metabolic pathway, 
presence of β-hydroxybutyrate in the blood is used to indicate successful implementation of the KD 
(Bough & Rho, 2007).  
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Although it has been almost a century since the diet’s conception, the exact mechanism 
of the KD remains poorly understood. It has been proposed that aside from ketone metabolism, 
the KD is responsible for other metabolic shifts that underlie the beneficial effects including: 
modification of the tricarboxylic acid cycle to increase neurotransmitter synthesis (adenosine and 
GABA), limit reactive oxygen species, and boost energy production in the brain. Such metabolic 
shifts are the basis for several hypotheses for the mechanism of action of the KD (Nylen, 
Likhoddii, & Burnham, 2009). Below, five of the most common hypotheses are briefly explored. 
The hypotheses share many similar components but attribute the clinical effectiveness to 
different biological aspects induced by the KD.  
 
1. The Ketone Hypothesis: Research conducted by Juge et. al (2010) has noted that ketone 
bodies compete with the chloride ions needed for release of the excitatory 
neurotransmitter glutamate from vesicular glutamate transporters. In addition to this 
suppression of neuronal excitation, ketone bodies have also been shown to enhance 
receptor function of the inhibitory neurotransmitter, GABA (Yang et al., 2007). The 
ability of ketone bodies to suppress glutamate and activate GABA indicates that that 
ketone bodies decrease the characteristic hyperexcitability associated with seizures. This 
hypothesis predicts that the ketone bodies present due to KD administration are directly 
responsible for the anticonvulsant effect on the brain (Nylen, Likhoddii, & Burnham, 
2009). 
2. Metabolic Hypothesis: This hypothesis is rooted in the idea that ketone bodies produced 
by the KD are a more efficient energy source than glucose (Nylen, Likhoddii, & Burnham, 
2009). In a study conducted by Appleton and De vivo (1974), it was reported that cerebral 
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energy reserves were significantly higher in their male albino rats on the KD versus a 
standard control diet. Appleton and De Vivo attributed this metabolic change to a high-
energy state of the brain cells from an increased ratio of ATP: ADP triggered by a high 
concentration of available fats and reduced carbohydrates. In addition to refractory 
epilepsy, the KD is also clinically used to treat glucose transporter protein syndrome and 
pyruvate dehydrogenase deficiency, both of which result in cerebral energy failure (Nordli 
& De Vivo, 1997). Additional research by Bough et al. (2006) demonstrated that 
compared to control animals, mice fed the KD for three weeks had a 46% increase in 
hippocampal biogenesis of mitochondria. These KD fed mice showed an up regulation of 
transcription factors that encode for mitochondrial protein which suggested an increased 
ATP production (Bough et al., 2006). The Metabolic Hypothesis postulates that once the 
body has become accustom to enzymatic and endocrine changes that accompany the KD, 
the increased activation of tricarboxylic acid cycle will increase cerebral energy via ATP 
production which stabilizes neuronal membrane potential, leading to greater seizure 
resistance (Zajac, et al., 2014; Bough et al., 2006).           
3. Amino Acid Hypothesis: It is suggested that KD modifies the products of the tricarboxylic 
acid cycle and alters the ratio of amino acid neurotransmitters, enhancing GABAergic 
inhibition (Nylen, Likhoddii, & Burnham, 2009). This hypothesis is rooted in the concept 
of GABA shunting, which is a regulating response thought to be mediated by the KD. In 
this theory, the GABA shunting reduces the amplitude of subsequent excitatory 
postsynaptic potentials and thereby reduces the hyperexcitability (McNally & Hartman, 
2012). Depending upon the neuronal network, GABA may have an anticonvulsant or 
proconvulsant effect, although research has indicated that cerebral GABA levels in male 
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albino rats are not altered compared to rats fed a standard control diet, local or regional 
GABA concentration differences may have a large effect on neuronal excitability and 
thereby reduce seizure frequency (Holmes, 1995; Al-Mudallah et al., 1996). 
4. Anti-Inflammatory and Lowered Reactive Oxygen Species Hypothesis: Previous 
research has shown that inflammation contributes to the development of chronic epilepsy 
and various other CNS diseases. Studies involving rodent models demonstrate that 
induced seizures trigger an inflammatory response that enhances neuronal excitability and 
propagates epileptic activity (Vezzani & Granata, 2005). Because inflammation is 
mediated by reactive oxygen species which are generated by polymorphonuclear 
neutrophils at the site of tissue damage, there is thought that the KD functions through an 
anti-inflammatory mechanism that effectively lowers reactive oxygen species (Mittal et 
al., 2014; Gasior et al., 2006). Specifically, a study by Maalouf et al. (2006) suggests that 
the ketone bodies produced through KD administration may decrease mitochondrial 
reactive oxygen species production by increasing mitochondrial uncoupling protein levels. 
This mechanism suggests that ketone bodies are more than a fuel source but they may 
have a cellular protective effect and function through an antioxidant mechanism (Kim et 
al., 2007).    
5. The Adenosine Hypothesis: As outlined in the Metabolic Hypothesis, the KD is thought 
to increase mitochondrial biosynthesis which in turn increases cerebral energy and brain 
ATP levels. The Adenosine Hypothesis is based on the observation that increased 
intracellular ATP will equilibrate and result in increased extracellular concentrations of 
ATP which is dephosphorylated into the neuromodulator, adenosine (Masino & Geiger, 
2008). Adenosine is a molecule typically present in the extracellular space of brain tissue 
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and is associated with neuronal inhibitory effects, sleep promotion, and seizure reduction 
(Dunwiddie and Masino, 2001). When adenosine binds to adenosine A1/A2 receptors, it 
has been shown to have an anticonvulsant effect; conversely, antagonism of A1/A2 
receptors leads to stimulant effects of rodent locomotion (Marston et al., 1986). Thus, it is 
thought that the KD increases adenosine A1/A2 receptor activation which hyperpolarizes 
neurons, closes calcium channels, decreases excitatory glutamate release, and adequately 
decreases neuronal excitability (Dunwiddie and Masino, 2001).   
 
Proposed Connection: Ketogenic Diet and ASD 
The Adenosine Hypothesis identifies key components of the neuromodulator, adenosine, 
which is ubiquitous in the CNS (Dunwiddie and Masino, 2001). In addition to its role as an 
anticonvulsant, researchers Poleszak and Malec identified that adenosine A2 receptor activation 
attenuated amphetamine-induced stereotypy in male Wistar rats, including increases rat 
grooming and increased head movements that interfere with goal-directed behavior (Polezak and 
Malec, 2003; Wolgin, 2012). With the core behavioral symptoms of ASD in mind – persistent 
social communication impairment and restricted and repetitive patterns of behavior – it has been 
proposed that activation of adenosine receptors may aid the core symptoms of ASD (Melmed & 
Cubells, 2016, Masino and Geigers, 2008). Based on the knowledge that epilepsy and ASD have 
a high rate of comorbidity, a shared underlying biological mechanism of reduced adenosine has 
been suggested (Brooks-Kayal, 2010). Figure 2 demonstrates the metabolic relationship between 
ketone bodies (BHB and acetoacetate) and the neuromodulator, adenosine.  
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Figure 2: In step 1, ketogenic metabolism yields ketone bodies which are transported to other 
tissues. In the ketolytic metabolism shown step 2, the ketones have been converted into acetyl 
CoA which enters the tricarboxylic acid cycle which channels protons and electrons into the 
electron transport chain. In step 3, the electron transport chain drives a gradient across the outer 
membrane of the mitochondria which creates ATP via ATP synthase. In step 4, a large 
ATP/adenosine ratio intracellularly leads to an extracellular increase of adenosine (Masino et al., 
2009).   
 
 
In 2002, a pilot study was conducted on the island of Crete to assess the role of the 
ketogenic diet in 30 children (ages 4-10 years) with autistic behavior. This population was of 
interest to researchers Evangeliou et al. (2003) because metabolic testing during a glucose 
challenge revealed high level of ketone bodies. It was thought that individuals in the population 
may have a mitochondrial energy production disturbance affecting the tricarboxylic acid cycle. If 
this is the case, it is supposed that increases ketone body synthesis will be activated in order to 
generate sufficient ATP. At the beginning of the study all children were classified with mild-
moderate (n=2) or severe ASD (n=28). Results indicated that of the patients that continued on 
the KD for a 6-month period experienced marked improvement in their social behavior, speech, 
hyperactivity, and other autistic behaviors (Evangeliou et al., 2003). Overall, there was a 60% of 
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the children on the KD improved on the Childhood Autism Rating Scale (Evangeliou et al., 
2003).  
Despite the promising results published by Evangeliou et al. (2003) suggesting the KD 
could help improve the behavioral symptoms to ASD, studies on children with ASD and the KD 
were not formally replicated until 2013 when researchers Herbert and Buckley conducted a case 
study of a young female diagnosed with both ASD and epilepsy (Herbert & Buckley, 2013). 
After pharmacological treatments failed to reduce seizures, she was switched to a gluten-free, 
casein-free diet and then added a low ratio KD (1.5:1). It was found that after 14 months of diet 
consumption her seizure frequency was greatly reduced and, most notably, her behavioral 
symptoms of ASD were markedly reduced; her score on the Childhood Autism Rating Scale 
decreased from 49 (severe autism) to 17 (score of 30 being the cutoff for ASD).     
The beneficial effects of the KD have also been shown in laboratory studies with rodent 
models.  Ruskin et al. (2013) fed juvenile BTBR mice, a murine autistic mouse model, and a 
strict 6:1 ratio of KD for three weeks. Following behavioral at 8 weeks of age, it was noted that 
the KD increased social interaction in a three-chamber test of sociability as compared with mice 
fed the control diet (Figure 3).  
 
 
 
 
 
 
 
 
 
 
Figure 3: Results demonstrating the effect of the KD in improving behavioral symptoms in BTBR mouse 
models. Notably, after only 3-5 weeks on KD, improvement in sociability and decreased repetitive 
grooming behavior was found (Ruskin et al, 2013).   
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KD and Diet Reversal 
 
More recent studies have used the KD to assess its efficacy in treating a myriad of 
different disorders including the behavioral symptoms of Rett syndrome, blood glucose levels 
and weight loss associated with type II diabetes, and the inflammatory environment of cancer 
(Evangeliou et al., 2003). Research by Lusardi et al., (2015) has considered the KD as a therapy 
to halt the development of epilepsy. In their study, rodents fed the KD for fifteen weeks showed 
a prolonged reduction of seizures which continued after a 4-day reversal to control diet. Methods 
of detecting epigenetic markers, such as a DNA methylation assay, were used to gather total 
genomic DNA from frozen tissue and assess global DNA methylation of KD and Reversal 
treatment groups compared to the CD group. Specifically, Lusardi et al. (2015), characterized the 
hippocampal 5-methylcytosine (5-mC) content with an ELISA based assay.  
It was found that animals maintained on the CD had and increased global DNA 
methylation status in whole hippocampal isolates, whereas KD-fed epileptic animals were found 
to have reduced levels of DNA methylation. This reduction of global hippocampal 5-mC more 
similarly resembled the methylation in CD-fed and KD-fed non-epileptic controls. Interestingly 
enough, this reduction of global hippocampal 5-mC status found to be maintained in the Reversal 
group over 8 weeks, after the switch back to the CD. Such results indicate that the KD does not 
only suppress seizures in adult mice and rats, but it is potentially effective in attenuating long-
term disease progression by its influence on epigenetics. Lusardi et al. (2015) provide evidence 
that the KD has an antiepileptogenic disease modifying effect capable of preventing the further 
development of epilepsy by impacting gene expression (Lusardi et al., 2015). This study 
provides evidence that there is a lasting effect of the diet that persist even when rodents are 
reversed to CD.  
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Figure 4: The image demonstrates the antiepileptogenic effects of a KD in the rat model of 
epilepsy. Experimental design is outlined in A – 6 weeks after drug induced status epilepticus, 
animals were randomly assigned to KD or CD. KD reversal to (KD-CD) was implemented in 
week 21. Shown in B, seizures in the KD-fed group were significantly reduced compared to 
control in weeks 18–21 while still on KD and this improvement persisted in week 27–29, after 
diet reversal (Lusardi et al., 2015).  
 
 
Persistent Pro-Social Effect of the KD:  
 
In this lab, a persistent effect of the diet has been noted in previous lab trials regarding 
the KD and male BTBR mice. In an unpublished study, it was found that after 12 weeks of KD 
administration, increased sociability was detected in mice that remained on the KD as well as 
with mice that underwent a 5-day reversal to the CD. Figure 5a demonstrates the timeline of the 
study, while Figures 5b and 5c outline the significant increase in pro-social behavior detected in 
phase 2 of the three-chamber test that was expected with mice remaining on the KD (5b) but 
unpredicted for mice reverted to the CD (5c). This suggests that like the Lusardi et al. (2105) 
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study, which demonstrated lasting seizure reduction despite diet reversal, the KD may have 
lasting pro-social effects that persist even when rodents are reversed to CD.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: In 5a, the timeline demonstrates KD diet administration and 5-day reversal to CD with 
a single behavioral test after 12 weeks and 5 days. Figures 5b and 5c show the increase in pro-
social behavior detected in both KD and Reversal groups.  
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THESIS OVERVIEW:  
As previously mentioned, there are many methods of treatment that exist to improve the 
core symptoms of autism, yet none of the various methods have been shown to reverse the 
disease process. This study is interested in the improved behavioral effects of the KD on autistic 
mouse models that may outlast diet consumption. This idea is rooted in the findings of Lusardi et 
al. (2105), regarding prolonged antiepiletogenic effect of the KD as well as findings from our 
own lab that that suggest pro-social behavior induced by the KD may have persistent effects. 
With these findings in mind, it is expected that enhanced sociability will continue even after 
reversal to the control diet. This will provide evidence that multiple benefits of the KD can 
endure beyond the time frame of diet administration. If this expectation holds true, further 
research may be done to demonstrate that the KD is more than a metabolic treatment that 
ameliorates symptoms, but a therapy that modifies the course of ASD.   
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MATERIALS AND METHODS 
Ethics Statement   
All procedures were performed in accordance with the NIH Guide for the Care and Use 
of Laboratory Animals, and approved by the Animal Care and Use Committee of Trinity College 
(A3869-01). 
 
Animals 
All behavioral testing was performed in adult male Black and Tan Brachyury T+ Itpr3tf/J 
(BTBR) mice, a mouse model of autism (Jackson Laboratories, Bar Harbor, ME). The BTBR 
strain is a result of selective inbreeding to develop the favorable phenotypic dark black fur coat 
with a notable light brown underbelly. In addition to fur color, throughout their lifespan BTBR 
mice have noticeable hair loss in tufted patterns due to a mutation, Itpr3tf (inositol 1,4,5-
triphosphate receptor 3; tufted), and they have short tail lengths due to T mutation (brachyury). 
Aside from their morphology, BTBR mice exhibit several symptoms of autism including: 
reduced social interactions, impaired play, low exploratory behavior, unusual vocalizations and 
high anxiety as compared to other inbred strains (McFarlane, 2008; Moy, 2007, Scattoni, 2008). 
Studies conducted for the Mouse Phenome Project indicate that BTBR have neurological 
difference including an absent corpus callosum and a severely reduced hippocampal commissure 
(Wahlsten D, 2003). These physiological differences may be the underlying causes of their 
displayed symptoms of autism.  
 
 
 
30 
 
Study Timeline  
At weaning, male BTBR mice (Jackson Laboratories, Bar Harbor, ME) were housed 
socially (3–6 per cage) and fed the standard rodent chow (CD; LabDiet 5001, W.F. Fisher & 
Son, Somerville, NJ). At five weeks of age, cages were assigned randomly to remain on control 
diet (n=11), switched to the 6:1 KD (F3666; BioServ, Frenchtown, NJ) (n=12), or the KD-CD 
reversal group (n=11). Initial three-chamber behavioral testing began at five weeks of age to 
provide baseline sociability data for each test group. A second round of behavioral testing 
occurred in all test groups after three 3 weeks after KD diet administration. Final testing occurred 
after 6 weeks of CD, KD, and after 5 days of reversal to CD for the KD-CD mice test group. 
Mice were all fed ad libitum and all measures were taken to minimize animal suffering. 
Figure 6: Study design timeline. All mice are male BTBR; Test 1 is a baseline at 5 weeks of age; 
Test is after 3 weeks on diet; Re-Test is after 6 weeks on diet and after 5-day reversal to CD. 
 
 
 
Baseline  Test  Re-Test  
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Weight & Blood Analysis:  Ketone and Glucose Levels  
In order to measure blood, all mice were briefly anesthetized by inhalation of isoflurane, 
a general anesthetic. Blood was then collected by nicking the lateral tail vein. The blood ketone 
(BHB) and glucose was measured using a Precision Xtra ketone/glucose meter and strips and 
recorded for each mouse. Increased blood concentration of BHB was taken as evidence of a high 
concentration of ketone bodies in the blood, ketonemia, in animals fed with the KD. The mice 
were placed back into their home cage to wake up and recovery from anesthesia.  
 
Behavioral Testing 
Three-Chamber Testing  
The three-chamber test is used to assess sociability and self-directed repetitive behavior is 
autistic mouse models. The three-chamber apparatus was made of Plexiglas and consisted of 
three equally-sized chambers (42.5 cm x 19.1 cm x 22.2 cm) separated by removable doors. 
These doors block entrance from the center chamber to the left and right side chambers. A wire 
cage (inverted pencil cup) was set against the back wall of each of the two side chambers. These 
were present for the entirety of testing. The three-chamber test is made up of two initial 
habituation phases and three recorded test phases and occurs for a total duration of 40 minutes. 
Before the start of a testing session, the cage of test mice were placed in the testing room, with 
the cage filter lid removed, to habituate to the testing room for 30 minutes. Simultaneously, the 
stranger mice (adult, male, from the same diet treatment as each test group) were placed under 
the two wire cups in the apparatus and left to habituate to the cups for 10 minutes (Figure 7A). 
Afterward, the stranger mice were returned to their cage and the apparatus was washed with 
warm water and soap to remove the scent of the stranger mice as well as any urine and feces 
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excreted from the stranger mice. Next, the subject mouse was placed in the center chamber with 
the doors blocking access to both left and right chambers. This lasted for 10 minutes and allowed 
the subject mouse to be familiar with the apparatus (Figure 7B). After habituation sessions for 
the stranger and subject mice were completed, a video-recording camera was setup to record the 
activity of the test mouse in the two 10 minute phases (Phase 1 and Phase 2) of the three-
chamber test for each group: CD, KD, and CD-KD reversal. 
In the first recorded video session, Phase 1, the doors of the side chambers were removed 
and the lid placed on top of the apparatus. The removal of the doors allowed the subject mouse to 
freely explore the left and right side chambers (Figure 7C) and this phase tested for side bias. At 
the end of the Phase 1 and before the start Phase 2, the subject mouse was gently guided back 
into the center chamber and the doors replaced, isolated the subject mouse in the center chamber. 
At this point, one stranger mouse was then placed under a wire cages in a side chamber and the 
cement block was placed to hold the wire cage in place. Next, the side doors were removed to 
allow the test mouse full access to the side chambers (Figure 7D). Phase 2 tested for social 
preference (time the subject mouse spent in the chamber with the stranger vs. time spent alone). 
At the end of the testing session, all mice were returned to their home cage and placed back in 
the mouse room. The entire three-chamber apparatus, including the removable doors, wire cages 
and cement blocks, was washed and dried.  
 
Phase 2: Sociability 
As mentioned above, phase 2 measures the tendency of the subject mouse to approach 
another mouse and engage in social investigation. In Figure 7C, one side chamber contains a 
stranger mouse that is contained in a wire cup that allows for visual, olfactory, auditory and some 
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tactile contact to be made while the side chamber contains the empty wire cage. Normal, healthy, 
mice are highly social animals that typically display social investigation of unfamiliar mice of 
the same species while BTBR mice demonstrate autistic-like behaviors (reduced social 
interactions, impaired play, low exploratory behavior) that were expected to interfere with 
sociability resulting in less time spent with the test mouse.  
 
 
Figure 7: Outline of the three-chamber test. (Svedova, 2011) 
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Statistical Analysis 
 
Data from the three chamber tests was scored by two independent researchers and at least 
one scorer was blind to dietary treatment. These data were entered into an Excel spreadsheet then 
analyzed based on time spent in each chamber. Sociability test in three-chamber Phase 2 test was 
defined as the ratio of time spent in the social chamber with the stranger mouse to the total time 
spent in side chambers. Mean, standard deviation, standard error of the mean and t-tests were run 
on all data and graphed with SigmaPlot software.  
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RESULTS   
 
Weight & Blood: Ketone and Glucose Levels 
Body weights and blood chemistry of each mouse was measured before treatment (five 
weeks of age; Baseline) as well as after three weeks of diet administration (eight weeks of age; 
Test) and after 6 weeks of diet administration (eleven weeks of age; Re-Test). Weight loss, 
increased ketone levels, and decreased glucose levels were found in KD and Reversal groups in 
the Test after 3 weeks of KD consumption. Additionally, weight, ketone, glucose levels returned 
to baseline after 5-day reversal to CD. 
 
 
 
Figure 8: This figure shows change in weights at 5 weeks of age as compared 8 and 11 
weeks of age for male BTBR mice in each treatment condition: CD, KD, and KD Reversal. 
There was a significant weight gain between Test and Re-Test as the Reversal group was 
switched to the CD (** p < 0.01).  
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Figure 9: KD increases blood ketone levels while reversal to CD returns ketone levels to 
baseline. There was a significant increase in ketone levels between the Baseline and first Test in 
both the KD and Reversal groups (KD: * p < 0.05; Reversal ## p < 0.01). The KD-fed group 
continued to have elevated ketone levels, while the Reversal group returned to baseline ketone 
levels (KD: * p < 0.05; Reversal ## p < 0.01).  
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Figure 10: KD decrease blood glucose levels while reversal to CD returns glucose levels to 
baseline. There was a significant decrease in glucose levels between the baseline test and the 
first Test in both the KD and Reversal groups (KD: ** p < 0.01; Reversal ### p < 0.001). The 
KD-fed group continued to have decreased blood glucose levels, while the Reversal group 
returned to baseline ketone levels (KD: ** p < 0.01; Reversal ### p < 0.001).  
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Three-Chamber Sociability Testing   
 
 The ratio of Phase 2, preference for sociability phase, compared to Phase 1, the non-
social phase was used to assess sociability in each treatment group: CD, KD, and Reversal. As 
expected, results suggest that the CD-fed BTBR mice did not spend significantly more time with 
a mouse-containing versus an empty chamber in any of the three tests, nor were the CD-fed mice 
found to be asocial. The first treatment group, KD-fed mice, showed neither an overall increase 
in sociability in the Test after three week of diet administration, nor in the Re-Test (after six 
weeks of diet administration) with was contrary to previous findings. Similarly, the Reversal 
group did not demonstrate significant changes in sociability in any of the three behavioral tests.   
 
 
 
 
Figure 11: CD has no effect on social preference in CD-Fed male BTBR mice in three 
chamber test. Figure shows that as expected, CD-fed mice had no significant behavioral 
changes characterized by time in chamber with stranger mouse in Phase 2 over total time in side 
chambers (n=11).   
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Figure 12: KD has no effect on social preference in KD-Fed male BTBR mice in three 
chamber test. KD-fed male BTBR mice did not exhibit significant pro-social behavior after 3 
weeks of KD (Test) or 6 weeks of KD (Re-Test) (n=12). These data conflict with previous 
research findings of Ruskin et al. (2013). 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Neither the KD nor Reversal to CD had a significant effect on social preference 
of male BTBR mice in three chamber test. Data reveals male BTBR mice demonstrated no 
significant pro-social behavior after 3 weeks of KD (Test) or after a 5-day reversal to CD (Re-
Test) (n=11). 
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Three-Chamber Sociability Testing – Mice Social on KD  
 
As the data does not indicate improvement in social behavior for the Reversal group in 
the three chamber Test (after 3 weeks of KD) compared to sociability in Baseline test, it remains 
difficult to draw conclusions regarding the persistent effects of the diet. For this reason, the mice 
which demonstrated increased sociability (ratio > 0.5 in Phase 2 of the Test, after 3 weeks of KD 
administration) were selectively isolated and re-analyzed.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: KD increase male BTBR sociability during three chamber testing. Data indicates 
KD-fed mice spent significantly more time in the target chamber during phase 2 than phase 1 in 
the Test after three weeks of KD (n=6, **p < 0.01). In the Re-Test, mice exhibited a tendency of 
increased sociability that approached significance ( + p < 0.09).  
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Figure 15: KD increase male BTBR sociability, while reversal to CD has no significant 
effect on behavior during three chamber testing. Data indicates while on the KD for three 
weeks (in Test), mice spent significantly more time in the in the chamber with the stranger 
mouse during phase 2 (n=5, **p < 0.01). However, after 5-day reversal to the CD, BTBR mice 
exhibited no significant pro-social behavior suggesting that the KD does not have persistent 
effects on sociability.     
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DISCUSSION 
 
In this study, blood, weight, and behavioral effects of the KD on juvenile male BTBR 
mice, a mouse model of autism spectrum disorder (ASD) were assessed. BTBR mice exhibit 
several symptoms of autism including: reduced social interactions, impaired play, low 
exploratory behavior, unusual vocalizations and high anxiety as compared to other inbred strains 
(McFarlane, 2008; Moy, 2007; Scattoni, 2008). BTBR mice at 5 weeks of age were randomly 
assigned to one of three diet groups: CD, KD, and Reversal. All mice underwent three-chamber 
behavioral testing followed by two periods lasting three weeks. During the first period, both KD 
group and KD reversal groups were switched to KD for three weeks and underwent three-
chamber behavioral testing. Subsequently, both groups underwent three additional weeks of KD, 
however in the last 5 days of the second period the reversal group was reverted to the CD and 
underwent their final three-chamber behavioral test.  
It was expected that at our baseline test (five weeks of age) all dietary treatment groups 
would be non-social, as they had been on the CD. After three weeks of diet administration (eight 
weeks of age), it was expected that the CD group would remain non-social while the KD and 
Reversal groups would demonstrate pro-social behaviors as previous studies have indicated that 
KD-fed BTBR mice showed behavioral improvements including an increased sociability in a 
three-chamber test after simply three weeks of diet administration (Ruskin et al., 2013). Finally, 
after six weeks of diet administration (11 weeks of age), it was expected that the CD would again 
remain non-social, the KD and Reversal groups would maintain their pro-social behaviors. The 
idea of a continued, or persistent, effect of the diet was rooted in previous lab findings that mice 
on the diet for 12 weeks demonstrated lasting positive behavioral alterations after a 5-day dietary 
reversal.  
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Our initial expectation that all male BTBR mice would demonstrate non-social behaviors 
was supported by our data. Additionally, as expected, our study found significant impact of the 
KD on blood levels and weight change; just three weeks after KD administration, in our second 
behavioral test, result show a significant increase in ketone levels and significant decrease in 
glucose levels for both KD and Reversal groups. Results for the Re-Test, 5 days after reversal to 
the CD, results indicate the reversal group is no longer in ketosis. Although our blood analysis 
revealed the hallmark characteristics of KD treatment, including weight loss, decreased glucose, 
and increased ketone levels, we did not successfully replicate the pro-social effects of the KD on 
behavior previously found by Ruskin et al. (2013, and unpublished data). Even when the mice 
that demonstrated pro-social behavior after three weeks on the diet in phase 2 of the behavioral 
test were isolated, there was only a slight hint that the KD had effect on behavior in the KD 
group. In the Reversal group, despite a significant appearance of pro-social behavior after three 
weeks on the diet, the mice fell back to baseline non-social behavior once they were switched to 
the KD. In sum, our results suggest the KD does not have persistent effects on sociability.     
It is unclear why we were unable to replicate improvement in sociability, which has  been 
demonstrated in the laboratory setting on multiple replications. Some ideas include the 
composition of our KD distributed by the company BioServ. One thought is that ingredients 
making up the 6:1 ratio of the KD may have been altered or the provider for the ingredients may 
have changed. Additionally, it is known that in any behavioral testing the external environment 
including temperature, lighting, noise, and scents can have a profound effect on animal behavior. 
Specifically, exposure to scents in a lab setting has been impacted in changing the social status 
and competitive in inbred male mice, including BTBR mouse models (Bine et al., 2013). It could 
be proposed that a change in environment may have induced a stress response in our mouse 
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models and thereby affected the pro-social effects of the KD. Additionally, in the unpublished 
laboratory data presented in in Figure 7, the persistent effect is based on a single three-chamber 
test after a 5-day reversal. This is in contrast with our methodology in which three behavioral 
tests were run. It is possible that the increased behavioral testing influenced behavior within our 
population of BTBR mouse models.  
As we move forward with this study, it is important to consider other behavioral tests for 
ASD-like behaviors. The core symptoms of autism include persistent social communication 
impairment and restricted and repetitive patterns of behavior. In this study, a single method of 
behavioral testing was used to assess sociability, however many other methods exist to test the 
social deficits that are characteristic of ASD including frontal contact analysis of the existing 
three-chamber videos and social transmission of food preference (STFP) tasks. STFP tests for 
social learning and the ability of a test mouse to observe and detect olfactory cues on a stranger 
mouse and learn to prefer a certain food based on the scent (Wrenn, 2004). Frontal contact is a 
measure of preference of reciprocal social interaction (Silverman et al., 2010). It was found that 
after three weeks on the KD, Ruskin et al. (2013) noted that male BTBR fed the KD had 
improved communication as they were trained to prefer a food based on social interaction and 
demonstrated a significant increase in frontal contact with stranger mice as compared to control 
diet-fed mice.   
In addition, the BTBR mouse strain has been shown to have abnormally high repetitive 
behaviors, namely grooming including in the three-chamber test. KD treatment has been shown 
to reduce these behaviors; therefore, it is possible to go back and reanalyze current video scores 
for grooming behavior. For this measure, we score for cumulative time spent grooming all body 
regions to analyze repetitive patterns. In terms of self-directed repetitive behavior, BTBR mice 
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fed the KD spent significantly less time grooming in both phase 2 of the three-chamber which 
suggested an improvement of one of the core symptoms of ASD (Ruskin et al., 2013). 
In the future, research regarding the diet reversal and persistent effects of the KD on 
autistic symptoms of BTBR mouse models may use a modified experiment timeline. Ours was 
modeled after the experiment conducted by Lusardi et al. (2105) that demonstrated rodents fed 
the KD for fifteen weeks showed a prolonged reduction of seizures which continued after a 4-
day reversal to control diet. Ongoing research may increase length of diet administration prior to 
reversal which may allow for increase epigenetic changes to take place. It would be interesting to 
use methods of detecting epigenetic markers, such as DNA methylation assay, to gather total 
genomic DNA from frozen tissue and assess global DNA methylation of KD and Reversal 
treatment groups compared to the CD group (Williams-Karnesky et al., 2013). This would 
provide evidence for changes that may be induced by the diet but do not affect behavior. Subtle, 
yet effective changes to study design may include a larger sample size and including additional 
measures of sociability including frontal contact and self-directed repetitive behaviors.  
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CONCLUSION 
This study focused on the BTBR mouse model to determine if improvement in ASD-
associated behaviors persists when animals are returned to a CD. Despite ketone, glucose, and 
weight changes data that represent hallmark characteristics of an effective KD treatment, we did 
not find significant improvements in sociability in either KD or Reversal groups. Further analysis 
of social animals in behavioral tests (after three weeks of diet administration) and Re-Test (after 
six weeks of diet administration) reveals a trend of pro-social effects of the diet in KD-fed group, 
however results do not provide support that increased sociability persists after diet 
administration. Ongoing research will focus on additional measures off sociability including 
frontal contact and self-directed repetitive behaviors.  
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